Inactivated SARS-CoV-2 vaccine does not influence the profile of prothrombotic antibody nor increase the risk of thrombosis in a prospective Chinese cohort.
Inactivated SARS-CoV-2 vaccine does not influence the profile of prothrombotic antibody nor increase the risk of thrombosis in a prospective Chinese cohort.
复制标题
在前瞻性中国队列中，灭活 SARS-CoV-2 疫苗不会影响促血栓抗体的特征，也不会增加血栓形成的风险
DOI：
10.1016/j.scib.2021.07.033
复制
发表时间：
2021-11-30
期刊：
影响因子：
18.9
通讯作者：
Qu J
中科院分区：
文献类型：
--
作者：
Liu T;Dai J;Yang Z;Yu X;Xu Y;Shi X;Wei D;Tang Z;Xu G;Xu W;Liu Y;Shi C;Ni Q;Yang C;Zhang X;Wang X;Chen E;Qu J
抗磷脂抗体的存在与2019冠状病毒病（COVID-19）患者的血栓形成有关。最近，根据多项研究报告，在腺病毒载体COVID-19疫苗接种者中，疫苗诱导的免疫性血小板减少是由抗血小板因子4 (PF4)-多阴离子复合物介导的。国内广泛使用的COVID-19灭活疫苗是否会影响血栓形成前自身抗体的产生并诱发血栓形成，目前尚不清楚。在这项前瞻性研究中，我们招募了406名医护人员，他们接受了两剂灭活的严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）疫苗（BBIBP-CorV，国药集团），间隔21天。接种前和第二次接种后4周的配对血液样本用于检测血栓形成前自身抗体，包括抗心磷脂（aCL）、抗β2糖蛋白I （a -β 2gp1）、抗磷脂酰丝氨酸/凝血酶原（aPS/PT）和抗pf4 -肝素。接种4周后，SARS-CoV-2特异性抗体血清转化率为95.81%（389/406）。在至少8周的随访期内，所有受试者均无自发性血栓形成或血小板减少症。接种前后10种自身抗体的存在无显著差异：aCL中IgG （7 vs. 8, P = 0.76）、IgM （41 vs. 44, P = 0.73）、IgA (4 vs. 4, P = 1.00)；反β2 gp1中,免疫球蛋白(7比6,P = 0.78), IgM(6和5,P = 0.76), IgA(3和5,P = 0.72);aPS / PT免疫球蛋白(0比0,P = 1.00), IgM(6和5,P = 0.76);apf4 -肝素（2比7，P = 0.18）和抗核抗体（ANA）（18比21，P = 0.62）。值得注意的是，7例接种后出现抗pf4 -肝素抗体（范围：1.18-1.79 U/mL），没有一例表现出血栓性障碍的迹象。综上所示，灭活SARS-CoV-2疫苗不影响抗磷脂抗体和抗pf4 -肝素抗体谱，不增加血栓形成风险。
The presence of antiphospholipid antibodies was shown to be associated with thrombosis in coronavirus disease 2019 (COVID-19) patients. Recently, according to reports from several studies, the vaccine-induced immune thrombotic thrombocytopenia is mediated by anti-platelet factor 4 (PF4)-polyanion complex in adenovirus-vectored COVID-19 vaccine recipients. It is impendent to explore whether inactivated COVID-19 vaccine widely used in China influences prothrombotic autoantibody production and induces thrombosis. In this prospective study, we recruited 406 healthcare workers who received two doses, 21 days apart, of inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (BBIBP-CorV, Sinopharm). Paired blood samples taken before vaccination and four weeks after the second vaccination were used in detecting prothrombotic autoantibodies, including anticardiolipin (aCL), anti-β2 glycoprotein I (aβ2GP1), anti-phosphatidylserine/prothrombin (aPS/PT), and anti-PF4-heparin. The seroconversion rate of SARS-CoV-2 specific antibodies was 95.81% (389/406) four weeks after vaccination. None of the subjects had spontaneous thrombosis or thrombocytopenia over a minimum follow-up period of eight weeks. There was no significant difference in the presence of all ten autoantibodies between samples collected before and after vaccination: for aCL, IgG (7 vs. 8, P = 0.76), IgM (41 vs. 44, P = 0.73), IgA (4 vs. 4, P = 1.00); anti-β2GP1, IgG (7 vs. 6, P = 0.78), IgM (6 vs. 5, P = 0.76), IgA (3 vs. 5, P = 0.72); aPS/PT IgG (0 vs. 0, P = 1.00), IgM (6 vs. 5, P = 0.76); aPF4-heparin (2 vs. 7, P = 0.18), and antinuclear antibody (ANA) (18 vs. 21, P = 0.62). Notably, seven cases presented with anti-PF4-heparin antibodies (range: 1.18–1.79 U/mL) after vaccination, and none of them exhibited any sign of thrombotic disorder. In conclusion, inactivated SARS-CoV-2 vaccine does not influence the profile of antiphospholipid antibody and anti-PF4-heparin antibody nor increase the risk of thrombosis.
登录
查看更多内容
DOI：
10.1056/nejmoa2104840
发表时间：
2021-06-03
期刊：
The New England journal of medicine
影响因子：
--
作者：
Greinacher A;Thiele T;Warkentin TE;Weisser K;Kyrle PA;Eichinger S
通讯作者：
Eichinger S
影响因子：
158.5
作者：
Ackermann, Maximilian;Verleden, Stijn E.;Jonigk, Danny
通讯作者：
Jonigk, Danny
影响因子：
27.4
作者：
Cervera, R;Font, J;Asherson, RA
通讯作者：
Asherson, RA
影响因子：
7.3
作者：
Borghi MO;Beltagy A;Garrafa E;Curreli D;Cecchini G;Bodio C;Grossi C;Blengino S;Tincani A;Franceschini F;Andreoli L;Lazzaroni MG;Piantoni S;Masneri S;Crisafulli F;Brugnoni D;Muiesan ML;Salvetti M;Parati G;Torresani E;Mahler M;Heilbron F;Pregnolato F;Pengo M;Tedesco F;Pozzi N;Meroni PL
通讯作者：
Meroni PL
影响因子：
3.5
作者：
Hursting MJ;Pai PJ;McCracken JE;Hwang F;Suvarna S;Lokhnygina Y;Bandarenko N;Arepally GM
通讯作者：
Arepally GM